{'fraction_non_alphanumeric': 0.04153549304356657, 'fraction_numerical': 0.03777800345282827, 'mean_word_length': 4.428886438809261, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Embryo/Fetus Doses from 18F-Fludeoxyglucose Radiopharmaceutical in Positron Emission Tomography/ Computed Tomography

Aim: The embryo/fetus may be accidentally exposed to ionizing radiation. The aim of this study is to calculate embryo/fetus doses in pregnant women who underwent F-18 fludeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scan. Materials and Methods: Between June 2015 and June 2021, 15 pregnant women underwent F-18 FDG PET/CT applied to the Genetic Research Center (GETAM). The OLINDA/EXM package program was used for internal radiation dosimetry according to the Medical Internal Radiation Dose scheme. FetDose V4 computer software was used to compute the embryo/fetus absorbed dose from CT scan. Results: The amount of the injected F-18 FDG activity to patients varied between 333 and 555 MBq. The mean embryo/fetal dose from F-18 FDG was 7.2 ± 2.8 mGy. In addition, the CT component dose to the embryo/fetus dose ranged from 8.5 to 16 mGy with a mean of 12.14 ± 2.05. Conclusions: The embryo/fetus dose from F-18 FDG PET/CT was <15 mGy, however, questioning the women's childbearing prior to scintigraphy is the first-line strategy to avoid accidental radiation exposure and stochastic risks.

global organizations, such as the International Commission on Radiological Protection (ICRP) and the National Council on Radiation Protection and Measurements. These regularities reported that fetal doses below 100 mGy should not be used as justification for terminating pregnancy. [5] According to the American College of Obstetricians and Gynecologists, potential health risks may arise after cumulative radiation exposure exceeding 50 mSv, depending on the dose and stage of pregnancy. [6] Since many radiopharmaceutical agents are utilized in nuclear medicine investigations, the variation in the radionuclide biokinetics and excretion rate complicates estimating dose to the embryo/fetus. [7] The aim of this study is to calculate fetal absorbed doses in pregnant women who were administered F-18 FDG. A further goal was to compare the fetus dose values generated from the mentioned procedures with the risk thresholds reported by ICRP 84. [5]

MaterIals and Methods
An ethics committee approval numbered 219488 was obtained from Cerrahpasa Medical Faculty for this study. Participants' consent was obtained using an assigned form.
Female patients who were administered 18 F-FDG radiopharmaceutical may realize afterward that they were pregnant at the time of PET/CT imaging. Therefore, they may approach a health institution to receive support from teratologic counseling services. In Turkey, Genetic Research Center (GETAM) at Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty provides the necessary services to pregnant patients from all other hospitals. One of the services is estimating the fetal absorbed dose by the medical physics department.
Between June 2015 and June 2021, embryo/fetus doses of 15 pregnant women who were administered F-18 FDG radiopharmaceuticals in different regions of Turkey and approached the GETAM were calculated retrospectively. Gestational age was obtained using ultrasound data. The characteristics of pregnant women who underwent PET/ CT are shown in Table 1. All of the pregnant women were in the first trimester of pregnancy and their gestational ages ranged from 4 weeks +4 days to 11 weeks +1 day (mean: 7.4 weeks ±2.6 days).
The OLINDA/EXM package program, employing the MIRD method was used to calculate the absorbed radiation dose resulting from radiopharmaceutical application. This code comprises standard reference phantoms for the adult female involving both pregnant and nonpregnant with three trimesters of pregnancy that are suitable for data analysis. Furthermore, it is allowed to modify the standard reference phantom with the patients' corresponding data such as patient weight. [8,9] Calculation of fetal doses OLINDA/EXM 1.0 software was used to calculate embryo/ fetus dose arising from nuclear medicine practices. All pregnant women were asked to bring the scan documents in order to collect detailed information about the procedure. The following equation [1] introduced by the MIRD for embryo/fetus dose calculation was applied in the current study: where D: absorbed dose in a target organ (mGy), Ã: cumulated activity in a source organ (MBq • h), A 0 : administered activity (MBq), t: residence time (h), and S is the dose factor provided in the program ( mGy MBq • h ).
Each radiopharmaceutical has different biokinetics in the human body and thus the effective half-life is also variable and must be derived separately for each patient and examination. Individual embryonal/fetal dosimetry is impossible as no prescan procedures could be tried for dose estimation. Instead, the 18 F-FDG kinetic data and the organs' specific residence time were generated from the phantom study reported by Russell et al. [10] The early, 3-month pregnant female model was selected for all calculations, and only the patient's weight was replaced in the program. The time-integrated activity coefficients for the fetuses (or the uterus for patient 1) were combined with the standard coefficients of the pregnant organs according to ICRP publication 106. [7] The time-integrated activity coefficients were entered into the residence time page shown in OLINDA/EXM, and then the code was run to generate the fetal doses.
FetDose V4 computer software was used to compute the fetus absorbed dose from CT. A set of equations were used to estimate the CT-related dose following PET/CT scans. [11] The fetal dose (D f ) from CT scans was calculated using the formula (2) as seen below: where CTDI is CT dose index, CTDI soft tissue (mGy/100 mAs) is the CTDI air to ICRU muscle (CTDI soft tissue = CTDI air × 1.07) used as approximations for the dose to soft tissue within the body, and NUD V is the sum of the normalized doses for all 5-mm slabs lying within the scan volume. [12] The calculated overall doses from CT and 18 F-FDG to embryo/ fetus were reported in the results section.

results
PET/CT scans were made at different nuclear medicine centers in Turkey. The amount of F-18 FDG activity injected into patients varied between 333 and 555 MBq. The mean embryo/ fetal dose from F-18 FDG was 7.2 ± 2.8 mGy. The embryo/ fetus dose from the CT component ranged from 8.5 to 16 mGy, with a mean of 12.14 ± 2.05 [ Table 2].
The number of fetuses corresponding to the pregnant women's gestational age intervals is shown in Figure 1. The relation between absorbed dose interval and the number of fetuses is shown in Figure 2.

dIscussIon
PET/CT embryo/fetus dosimetry is performed in two stages: first, the calculation of dose resulting from 18 F-FDG, and then, the CT dose contribution is estimated. The fetal dose from F-18 FDG has been reported as 0.81 mGy/mCi (0.0219 mGy/ MBq) in the early and 3-month period of pregnancy. [10,[13][14][15] In our study, the embryo/fetal dose per unit activity was found to be 0.0104 ± 0.0081 mGy/MBq. Zanotti-Fregonara et al. calculated the total fetal dose of 21.0 mGy for a pregnant   woman undergoing PET/CT, and reported that 10 mGy of that dose arose from CT scan. [14] The present results showed that an average radiation dose of 8.19 ± 0.83 mSv and 13.44 ± 5.14 mSv from PET and CT components, respectively, resulted in a total dose of 21.64 ± 5.20 mSv. [15] The total effective dose ranged from 8.0 to 24.05 mSv using General Electric Healthcare (Discovery STE, 16, BGO) and 8.35-26.85 mSv using Philips Medical Systems (Gemini TF 16, LYSO) scanner, resulting in differences of 4.3%-15% for the low-dose scan and 4.1%-11% for standard-dose scans. The CT component contribution to the total dose was between 32% and 77% for GE, and 35% and 79% for Philips. [16] Huang et al. [17] reported that the fetal dose from 328 MBq 18 F-FDG was 6.25 mSv, and Liu et al. [18] likewise reported fetal dose from 370 MBq 18 F-FDG as 6.28 mSv. Zanotti-Fregonara et al. [1] reported that fetal doses from 328 MBq F-18 FDG ranged from 6.29 x 10-3 to 2.46 x 10-2 mGy/MBq mGy/MBq in six cancer women with known pregnancy. [1] Takalkar et al. [19] reported that the fetal dose from 173.9 to 340.4 MBq F-18 FDG was estimated to be 9.04 mGy in five women with known pregnancy.
In our study, the mean embryo/fetus dose from F-18 FDG was found to be 7.2 ± 2.8 mGy. In general, 6-16-slice diagnostic CT is used in PET/CT equipment ensuring a relatively low dose from CT. However, the dose level may change in CT scan according to the CTDIvol value for each patient. [20] Hsieh et al. [21] reported in 2012 that patients in their first trimester had a fetal dose of 6.3 mGy from F-18 FDG, and a CT dose as low as 3.6 mGy leading to a total dose of 9.9 mGy. In contrast, our study showed that the mean embryo/fetus dose from CT scan was 12.14 ± 2.05 mGy, while the mean embryo/ fetal dose from 456.3 ± 82.3 MBq F-18 FDG activity was 7.2 ± 2.8 mGy. The total embryo/fetus dose resulting from PET/CT procedure was 19.34 ± 3.5 mGy.
conclusIons ICRP Publication 84 states that radiation-induced malformations have a threshold of 50-100 mGy (5-10 rad). Accordingly, the diagnostic nuclear medicine examinations often induce fetal dose less than the dose threshold (50-100 mGy) of the teratogenic effects reported by ICRP 84. Thus, fetal doses below 100 mGy should not be considered a reason for terminating a pregnancy after radiation exposure.
The embryo/fetus dose from F-18 FDG PET/CT was less than 50 mGy which is the threshold dose for teratogenic effects dose, however, questioning the women's childbearing prior to scintigraphy is the first-line strategy to avoid accidental radiation exposure and the arising stochastic effects.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.